Abbott has secured the US Food and Drug Administration (FDA) approval for its next-generation CardioMEMS HERO device, which is designed to support remote heart failure monitoring. The new pulmonary ...
Abbott Laboratories recently received FDA approval for its redesigned CardioMEMS Hero remote heart failure monitoring system, featuring a smaller, lighter reader aimed at improving patient convenience ...
CardioMEMS ran into a regulatory roadblock last week, when an FDA advisory panel recommended that the agency not approve the company's Champion HF Monitoring System. The device is said to be the first ...
The CardioMEMS HF System is proven to significantly reduce heart failure hospitalizations and improve quality of life in NYHA class III HF patients St. Jude Medical now intends to exercise its ...
WASHINGTON (Reuters) - A Food and Drug Administration review of CardioMEMS' device for treating heart failure found it has met its main safety and effectiveness goals, based on trial results. But the ...
Oak Ridge, TN, March 23, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (DXR) (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the ...
ATLANTA, Aug. 26 -- CardioMEMS, Inc., a medical technology company that has developed and is commercializing proprietary wireless sensing and communication technology for the human body, today ...
Oak Ridge, TN, July 12, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (DXR) (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces a new research letter in the Journal ...
WASHINGTON, Dec 5 (Reuters) - U.S. health regulators on Monday said a CardioMEMs implant for treating heart failure met its main safety and effectiveness targets but warned of potential bias in the ...
December 8, 2011 (Gaithersburg, Maryland) — An FDA advisory panel collectively decided a tiny pulmonary-artery (PA) pressure monitor for patients with heart failure (HF) isn't ready for prime time.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results